Alvotech (ALVO) Discusses Launch of $125 Million Commercial Bond Offering and Business Update Transcript

SA Transcripts157.38K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Alvotech (ALVO) Discusses Launch of $125 Million Commercial Bond Offering and Business Update December 16, 2025 12:00 PM EST Company Participants Robert Wessman - CEO, Founder & Executive ChairmanJoseph McClellan - Chief Operating OfficerLinda Jonsdottir - Chief Financial Officer Presentation Operator Okay, everyone. Welcome to this global investor call in connection with Alvotech launching up to $125 million convertible bond offering. I'm pleased to introduce the CEO of the company; Robert Wessman, the CFO of the company; Linda Jonsdottir, the CEO; Joseph McClellan, and the Head of Investor Relations, which is Patrik Ling. There is one page in the presentation with the convertible bond terms. We can go through that afterwards. There will also be a Q&A session [Operator Instructions]. But now I will hand over to the CEO, Mr. Robert Wessman. Robert WessmanCEO, Founder & Executive Chairman Yes. Thank you so much. First of all, I want to thank you, everyone, for joining in here today, and this was on a short notice, I guess, for some. So thanks for joining. We will have 15 minutes presentation, so we will go fairly fast through the deck, but as mentioned, we will have a Q&A in the end. So the company was founded 2013 by myself and other investors which came in later on. We wanted to build out one of the leading biosimilar companies in the world. And the key ingredients being best-in-class R&D, best-in-class manufacturing, strong portfolio and pipeline and then having a global marketing reach. Since 2013, we have invested around $2 billion into the business. We have around 30 products in the pipeline, in the development pipeline. We have now five products outside U.S. on some of the key markets. And we have two products for now until we clear the CRL, which is out there for the pending approval until next